Motility News

Electroacupuncture increased weekly spontaneous bowel movements and improved quality of life in patients with cancer and opioid-induced constipation, according to data published in JAMA Network Open.

Vaccination against COVID-19 is strongly recommended in patients with celiac disease, who are at greater risk for hospitalization due to SARS-CoV-2 infection compared with people who do not have celiac disease, according to research.

Colesevelam was superior to placebo in inducing remission in patients with bile acid diarrhea with no serious adverse events reported, according to results published in The Lancet Gastroenterology & Hepatology.

Use of the investigational microbiome therapeutic SER-109 resulted in rapid and steady improvement in disease-specific quality of life for patients with recurrent Clostridioides difficile infection, according to data in JAMA Network Open.

The FDA cleared the investigational new drug application for ExeGi Pharma LLC’s, EXE-346, a live biotherapeutic biologic drug intended for patients with ileal pouch-anal anastomosis who experience excessive stool frequency.

The FDA has approved Axonics Inc’s fourth-generation R20 rechargeable sacral neuromodulation system for bladder and bowel dysfunction.

The ACG has published updated guidelines for the evaluation, diagnosis and management of children and adults with celiac disease.

Irritable bowel syndrome may result from ineffective anatomical, physiological and neuropsychological gravity-management systems, a researcher theorized in an article published in The American Journal of Gastroenterology.

Chronic constipation affects up to 20% of adults and 16% of children in the U.S, therefore the International Foundation for Gastrointestinal Disorders recognized December as Constipation Awareness Month.

Food insecurity among women was associated with a higher likelihood of fecal incontinence, even when accounting for diet, according to data published in the American Journal of Obstetrics & Gynecology.